Recommendation of the President – Enhertu (trastuzumab deruxtecan)

On 26 June 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 83/2025 on the appraisal of the drug Enhertu (trastuzumab deruxtecan) under the drug program “Treatment of patients with cancer of the esophagus, gastroesophageal junction, and stomach (ICD-10: C15-C16)”

Publication in Public Information Bulletin (BIP) >>